What investor type does Regeneron Pharmaceuticals fit best in FoxScore?

Regeneron Pharmaceuticals fits a trend/momentum-oriented investor type in FoxScore: trend is clearly the strongest sub-score. This can be useful if you follow trends — but pay close attention to stability (drawdowns/volatility) because trend signals can flip quickly.

How meaningful is the available history for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.

What is FoxScore good for — and what is it not for?

FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.

Analysis for Regeneron Pharmaceuticals

REGN · As of: 02/17/2026

Basic information

Type: Stock

Region: US

Sector: Health Care

TER: –

History

Available history:15.0 years

Last tradingday:02/17/2026

Description & usage

Regeneron Pharmaceuticals is a biotechnology company focused on innovative medicines, including in ophthalmology, immunology and oncology. Key factors include sales of core products, pipeline progress, clinical results and regulatory approvals. Patents, competition and pricing/reimbursement pressure affect long-term profitability.

Scale: 0 = weak, 50 = average, 100 = top

Analysis summary

Regeneron Pharmaceuticals (REGN) currently has a total score of 48 points, placing it in the neutral range. The score is made up of Performance (44), Stability (41) and Trend (68). The profile is clearly uneven: Trend stands out while Stability is more neutral.

Performance scores 44 points (neutral). Most supportive metric: 1Y return at 16.6 %. Weaker metric: 3Y return at 5.6 %.

Stability scores 41 points (neutral). Key strength: Sortino ratio (90d) at 3.86. Weaker metric: max drawdown (1Y) at -59.8 %. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.

Trend scores 68 points (strong). Key strength: Price is about 25.0 % above SMA200. Main drag: Price is about 3.3 % above SMA50.

Overall, the picture is mixed: Trend does the heavy lifting while Stability holds the score back. On a metric level, Sortino ratio (90d) stands out, while max drawdown (1Y) is the main weak spot.

(Historical evaluation, not investment advice.)

Chart anzeigen

Wenn du fortfährst, wird der Chart von TradingView geladen. Dabei können Daten (z. B. deine IP-Adresse) an TradingView übertragen werden.

Overall score

neutral

Scores

Metrics

FAQ

What investor type does Regeneron Pharmaceuticals fit best in FoxScore?: Regeneron Pharmaceuticals fits a trend/momentum-oriented investor type in FoxScore: trend is clearly the strongest sub-score. This can be useful if you follow trends — but pay close attention to stability (drawdowns/volatility) because trend signals can flip quickly.
How meaningful is the available history for Regeneron Pharmaceuticals?: Regeneron Pharmaceuticals currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
What is FoxScore good for — and what is it not for?: FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.